STAT+: Massachusetts biotechs seek to piggyback on weight loss drug boom
The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and…
Category: Pharmaceuticals
STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments
MADRID — If you had to pinpoint one subject that stood out at this year’s…
STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short
Earlier this month, the U.K. government issued a proposal to gather information and opinions about…
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs…
STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson…
Johnson & Johnson antiviral pill for dengue shows early efficacy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a…
.jpg)
STAT+: Eli Lilly, riding a hot streak, expects to double planned employment in Boston research center
Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro
As demand for weight-loss treatments intensifies, Eli Lilly has filed a complaint with the U.S….
Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
STAT+: How biotech deal-making really works behind the scenes, according to founders
What does it feel like to run a biotech startup and then get “the call”…
STAT+: GSK CEO on pharma giant’s new direction: ‘We’re in the business of preventing and treating disease’
The story of GSK is one of reinvention, CEO Emma Walmsley said at the STAT…
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program…
STAT+: Biotech investors push to extend time before pills are subject to price negotiations
The fight over drug prices is far from over. Investors in biopharma companies, who lobbied…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
Opinion: STAT+: Preventive drugs may be the best solution to the antibiotic resistance crisis
The antibiotics crisis is a silent pandemic that threatens to knock modern society back into…
.jpg)
As Pfizer slashes revenue projections, Moderna says it “remains comfortable”
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
STAT+: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
In the latest tussle over the cost of medicines, Teva Pharmaceuticals has filed a lawsuit…
Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Doctors — and patients — must seek alternatives to long-term steroids
Steroids were once the only treatment option for some chronic conditions. Today, many other treatments…
STAT+: Eye docs urge Medicare to lower insurance hurdles amid shortage of repackaged Avastin
Due to a shortage of a widely used compounded medicine for serious eye diseases, two…
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Cell and gene therapies could be a safer bet than other drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Peter Marks on creating Operation Warp Speed, but for rare diseases
Peter Marks wants drug developers to ask more stupid questions. It’s part of the top…
STAT+: Life sciences deals on track to hit lowest point since 2017
It’s no secret that biotech industry funding has fallen from its Covid highs. But with…
STAT+: CRO claims there was no misconduct in Lyme vaccine trial it ran for Pfizer
A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine…
With Ozempic, Wall Street moves on from a whole other class of medicines
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Want a biotech buyout? Target cancer
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart…
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…
Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’
The shortage of cancer drugs is not going away, but it may be easing slightly,…
Scientists want to put carbon footprints on drugs. But it’s hard to get accurate numbers
Anyone picking up a prescription from their pharmacy is used to the reams of paper…
Opinion: Phenylephrine is no better than a placebo. What if that’s still better than nothing?
As the temperatures cool, the season of colds, flu, and now Covid-19 is heating up….
STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug…
STAT+: Key Senate panel eyes action on drug shortages
WASHINGTON — One of the top health care committees in the Senate is assembling ideas…
STAT+: FDA cites Fresenius Kabi for contamination problems that CDC linked to deadly sepsis cases
Several cases of sepsis — three of which ended in patients deaths — were traced…
STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV
In the latest battle over access to medicines, Colombian authorities have decided to issue a…
When is a Wall Street disappointment ‘good enough’ for the FDA?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Court strikes down Trump-era rule that allowed health insurers to broadly use copay accumulators
A U.S. judge has struck down a Trump administration rule that allowed health insurers not…
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?
Next week, 50 medical experts from the Karolinska Institutet in Stockholm will meet to award…
STAT+: Unitaid slams J&J over pricing and patents for a tuberculosis drug
In a highly unusual move, Unitaid has publicly criticized Johnson & Johnson over its pricing…